<DOC>
	<DOCNO>NCT02182622</DOCNO>
	<brief_summary>The purpose study first determine high dose LDE225 combine wtih Docetaxel Prednisone give cause unacceptable side effect give patient castrate resistant prostate cancer fail previous docetaxel therapy .</brief_summary>
	<brief_title>LDE225 + Docetaxel/Prednisone Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Male patient 18 year old Histologically document prostate adenocarcinoma progressive systemic ( clinically metastatic disease document bone , CT MRI scan ) disease despite castrate level testosterone due orchiectomy Luteinizinghormonereleasing hormone ( LHRH ) antagonist Must receive prior Docetaxel treatment evidence disease progression AND least one ( e.g . Abiraterone Acetate , Enzalutamide , Cabazitaxel , Radium223 ) four FDA approve therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 01 At least one measurable site disease ( define Response Evaluation Criteria Solid Tumors ) specific response assessment criterion appropriate Able swallow retain oral medication Must castrate level testosterone ( =/ &lt; 50ng/dl 1.7nmol/L ) . Castrate status must maintain continue gonadotropinreleasing hormone ( GnRH ) analogues unless patient undergone surgical orchiectomy Discontinuation antiandrogen ( except GnRH analogues patient continue GnRH analogue maintain castrate level study ) , antineoplastic investigational treatment =/ &gt; 4 week ( 6 week bicalutamide ) Must document progressive disease previous line therapy accord Prostate Cancer Working Group 2 ( PCWG2 ) criterion : patient progress base solely Prostate Specific Antigen ( PSA ) rising , sequence rise value 3 consecutive occasion least 1 week interval 5.0ng/mL minimum level entry ; patient manifest disease progression per Response Evaluation Criteria Solid Tumors ( RECIST ) eligible independent PSA ; patient manifest bone progressive disease , accord PCWG2 eligible . Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 10^9/L Hemoglobin ( Hgb ) ≥ 9 g/dL Platelets ≥ 80 x 10^9/L Serum total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Aspartate Aminotransferate ( AST ) Alanine Transaminase ( ALT ) ≤ 2.5 x ULN ≤ 5 x ULN liver metastases present Plasma creatine phosphokinase ( CK ) &lt; 1.5 x ULN Serum creatinine ≤ 1.5 x ULN 24hour clearance ≥ 50ml/min Asymptomatic minimally symptomatic patient docetaxel naïve metastatic castration resistant prostate cancer Patients major surgery within 4 week initiation study medication Patients concurrent uncontrolled medical condition may interfere participation study potentially affect interpretation study data Patients unable take oral drug lack physical integrity upper gastrointestinal tract know malabsorption syndrome ( e.g. , ulcerative colitis , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) Patients previously treat systemic LDE225 Hh pathway inhibitor Patients active uncontrolled symptomatic central nervous system ( CNS ) metastases History hypersensitivity LDE225 drug similar chemical class Patients neuromuscular disorder ( e.g . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis spinal muscular atrophy ) concomitant treatment drug recognize cause rhabdomyolysis , 3hydroxy3methylglutarylcoenzyme A ( HMG CoA ) inhibitor ( statin ) , clofibrate gemfibrozil , discontinue least 2 week prior start LDE225 treatment . If essential patient stay statin control hyperlipidemia , pravastatin may use extra caution Patients plan embark new strenuous exercise regimen initiation study treatment : Muscular activity , strenuous exercise , result significant increase plasma CK level avoid LDE225 treatment Patients take part experimental drug study within 4 week 5 halflives , whichever longer , initiate treatment LDE225 Patients receive antineoplastic therapy besides Docetaxel ( e.g . chemotherapy , target therapy radiotherapy ) concurrently within 2 week start treatment LDE225 Patients receive treatment medication know moderate strong inhibitor inducer Cytochrome P450 3A4/5 ( CYP3A4/5 ) drug metabolize Cytochrome P450 2B6 ( CYP2B6 ) Cytochrome P450 2C9 ( CYP2C9 ) narrow therapeutic index , discontinue start treatment LDE225 . Medications strong CYP3A4/5 inhibitor discontinue least 7 day strong CYP3A/5 inducer least 2 week prior start treatment LDE225 Patients require use warfarin ( substrate CYP2C9 ) enrol LDE225 competitive inhibitor CYP2C9 base invitro data Impaired cardiac function clinically significant heart disease , include one following : Angina pectoris within 3 month Acute myocardial infarction within 3 month QTcF &gt; 450 msec male &gt; 470 msec female screen ECG A past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome Other clinically significant heart disease ( e.g . congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Prior study entry ECG abnormality document investigator medically relevant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>